N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

DB13948ExperimentalSmall molecule

25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was... It was discovered in 2014 at the University of Copenhagen.

Mechanism: 25CN-NBOH is one of the most selective agonist ligands for the 5-HT2A receptor discovered. It has a pKi of 8.88 at the human 5-HT2A receptor and is 100x more selective for 5-HT2A over 5-HT2C, and 46x more selective for 5-HT2A over 5-HT2B.
Curator reviewed · 2 references
Formula / weight: C₁₈H₂₀N₂O₃ · 312.369 g/mol (avg)
Also known as: 25CN-NBOH · NBOH-2C-CN

Resolves to

Compound

UNII32CN2DQE3QCAS1391489-32-9

Structure

InChIKeyVWEDZTZAXHMZIL-UHFFFAOYSA-NSMILESCOC1=CC(C#N)=C(OC)C=C1CCNCC1=C(O)C=CC=C1

Targets

P28223HTR2A

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

707Drug interactionsStructured to mechanism, not free text

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account